---
layout: default
title: Alpha -Tocopherol Acetate Dl- 5-Methyltetrahydrofo
parent: 僅模型預測 (L5)
nav_order: 230
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Dl- 5-Methyltetrahydrofo
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Prenatal Nutritional Supplement Combination: Repurposing Evaluation Pending

## One-Sentence Summary

This candidate is a 14-component nutritional supplement combination — including omega-3 fatty acids (DHA/EPA), active folate (5-MTHF), iron, iodine, and multiple vitamins — whose composition strongly suggests a prenatal or maternal nutrition indication.
However, the TxGNN model returned **no predicted indications** for this candidate, and the drug is **not registered** in Taiwan under any authorization number.
Without regulatory baseline data or model output, this evaluation cannot progress beyond preliminary triage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no Taiwan registration found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — but no output generated) |
| US Market Status | Not marketed in Taiwan (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This candidate's INN string contains **14 co-listed active ingredients**, which is highly atypical for a single-entity drug repurposing query. The TxGNN knowledge graph is designed to evaluate individual compounds or well-defined combinations with a DrugBank anchor ID. The likely reasons for prediction failure are:

1. **No DrugBank ID available** — the system could not anchor this multi-component string to a graph node, so no traversal was performed.
2. **Multi-ingredient query string not parseable** — the semicolon-delimited INN list was treated as a single unrecognized entity rather than a decomposed set of components.
3. **No Taiwan regulatory baseline** — zero approved licenses means there is no approved indication to seed the "original indication → new indication" inference pathway.

The composition itself is clinically recognizable: DHA + EPA (omega-3 for fetal neurodevelopment), 5-MTHF + Folic Acid (neural tube protection), Ferrous Asparto Glycinate (pregnancy anaemia prevention), Cholecalciferol + Pyridoxine + Cyanocobalamin + Biotin (B-complex and vitamin D), Potassium Iodide (thyroid function in pregnancy), and Magnesium Oxide + Calcium Formate (bone and muscle support). This profile is consistent with a **branded prenatal multivitamin** — analogous to products such as Elevit, Materna, or Femibion — that may be marketed in other jurisdictions but has not been registered in Taiwan.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component combination as a unified query.

> **Note:** Individual components (e.g., folic acid for neural tube defects, DHA for preterm birth prevention) have extensive independent trial records. Re-running TxGNN queries per ingredient would be required to surface this evidence.

---

## Literature Evidence

Currently no related literature available under this combined query.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No DDI data, warnings, or contraindications were returned for this combination query. Safety evaluation of individual components (particularly iron, vitamin D, and iodine, which carry dosing risks at high levels) should be conducted separately before any clinical use assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not process this candidate because no DrugBank ID was resolved and no Taiwan regulatory baseline exists; without graph anchoring, no repurposing inference is possible.

**To proceed, the following is needed:**

- **Decompose the query:** Split the 14-component INN string into individual ingredients and re-run TxGNN for each active component separately (priority: Doconexent/DHA, Icosapent/EPA, 5-Methyltetrahydrofolic Acid, Cyanocobalamin)
- **Identify the originator product:** Determine the brand name and jurisdiction of registration (e.g., EU, US, Japan) to obtain a regulatory anchor and approved indication text
- **Resolve DrugBank IDs:** Map each ingredient to its DrugBank entry to enable graph traversal and MOA retrieval
- **Obtain safety baseline:** Download the originator product's package insert to populate warnings, contraindications, and DDI data (Data Gaps DG001, DG002)
- **Re-triage as prenatal indication:** If confirmed as a prenatal supplement, evaluate whether repurposing analysis at the ingredient level (vs. combination level) is the appropriate analytical unit for this pipeline
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

